NEW YORK (GenomeWeb) – The San Antonio 1000 Cancer Genomes Project (SA1KCGP), WuXi NextCode, and South Texas Accelerated Research Therapeutics (START) today announced a partnership to analyze cancer genomes.
START has contracted with WuXi NextCode to sequence and interpret samples from the SA1KCGP collection of breast, lung, prostate, skin, colorectal, uterine, pancreatic, ovarian, stomach, and brain cancers. START will connect the genomic data to anonymized phenotypic data in patient electronic medical records and make it available to researchers and clinicians, the partners said in a statement.
"WuXi NextCODE was the logical partner in genomics," START Director of Clinical Research Anthony Tolcher said in a statement. "They bring to this project the same expertise they are deploying in large-scale precision oncology initiatives from Genomics England to Qatar, backed by the renowned clinical development capabilities of WuXi AppTec."
Last month, WuXi NextCode signed a deal with Qatar's Sidra Medical and Research Center to develop bioinformatics programs and serve as the informatics platform for the Qatar Genome Project.
SA1KCGP said in a statement it is the largest community-wide project of its kind, linking genomic data to clinical outcomes. START is a contract research organization with locations in San Antonio, Madrid, and Shanghai.